<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Isocarboxazid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01247</strong>&#160; (APRD00701)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An <span class="caps">MAO</span> inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From <span class="caps">AMA</span>, Drug Evaluations Annual, 1994, p311)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01247/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01247/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01247.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01247.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01247.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01247.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01247.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01247">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Isocarboxazida</td><td>Spanish</td><td>INN</td></tr><tr><td>Isocarboxazide</td><td>French</td><td>INN</td></tr><tr><td>Isocarboxazidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Enerzer</td><td>Takeda</td></tr><tr><td>Isocarboxazid</td><td>Alliance</td></tr><tr><td>Marplan</td><td>Validus</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li>
<li><a href="/mesh/monoamine-oxidase-inhibitors">Monoamine Oxidase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>59-63-2</td></tr><tr><th>Weight</th><td>Average: 231.2505<br>Monoisotopic: 231.100776675</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>XKFPYPQQHFEXRZ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Alternative parents</th><td>Isoxazoles; Carboxylic Acid Hydrazides; Polyamines; Enolates; Carboxylic Acid Amides; Hydrazines and Derivatives</td></tr><tr><th>Substituents</th><td>azole; isoxazole; carboxylic acid hydrazide; carboxamide group; carboxylic acid derivative; polyamine; enolate; hydrazine derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>May be used to treat major depressive disorder. </td></tr><tr><th>Pharmacodynamics</th><td>Isocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression.</td></tr><tr><th>Mechanism of action</th><td>Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase&#8211;A (MAO-A) and monoamine oxidase&#8211;B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.</td></tr><tr><th>Absorption</th><td>Well absorbed from the gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic and rapid (by oxidation).</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9783</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5531</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6987</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9138</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9716</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8247</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8471</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8141</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6057</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8885</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8518</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5973
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Carcinogens  
        </td>
        <td>
            0.5
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9227
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9486 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9209
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9069
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Validus pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.oxfordpharm.com">Oxford Pharmaceutical Services Inc.</a></li>
<li><a href="http://www.validuspharma.com">Validus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00488">Altretamine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. </td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like isocarboxazid. </td></tr><tr><td><a href="/drugs/DB00484">Brimonidine</a></td><td>MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB00921">Buprenorphine</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Possible blood pressure elevation</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Risk of hypertensive crisis.</td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Possible severe adverse reaction</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00841">Dobutamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00494">Entacapone</a></td><td>Possible hypertensive crisis with this combination</td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Isocarboxazid may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01235">L-DOPA</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00150">L-Tryptophan</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01365">Mephentermine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00610">Metaraminol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00723">Methoxamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00422">Methylphenidate</a></td><td>Possible hypertensive crisis with this combination</td></tr><tr><td><a href="/drugs/DB00211">Midodrine</a></td><td>Possible hypertensive crisis with this combination</td></tr><tr><td><a href="/drugs/DB04896">Milnacipran</a></td><td>Increase serotonin levels. Combination therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Potentially fatal adverse effects</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00830">Phenmetrazine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00388">Phenylephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00323">Tolcapone</a></td><td>Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals, avoid tyramine, caffeine and alcohol.</li></ul></td></tr></tbody></table>